1. Home
  2. GSL vs SDGR Comparison

GSL vs SDGR Comparison

Compare GSL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSL

Global Ship Lease Inc New

N/A

Current Price

$43.03

Market Cap

1.5B

ML Signal

N/A

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

N/A

Current Price

$28.90

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GSL
SDGR
Founded
2007
1990
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
GSL
SDGR
Price
$43.03
$28.90
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
★ $51.00
$33.57
AVG Volume (30 Days)
254.8K
★ 1.7M
Earning Date
11-09-2026
11-04-2026
Dividend Yield
★ 6.34%
N/A
EPS Growth
N/A
★ 45.14
EPS
★ N/A
N/A
Revenue
N/A
★ $255,869,000.00
Revenue This Year
$4.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.49
★ N/A
Revenue Growth
N/A
★ 23.29
52 Week Low
$32.74
$10.95
52 Week High
$46.57
$34.00

Technical Indicators

Market Signals
Indicator
GSL
SDGR
Relative Strength Index (RSI) 55.61 54.84
Support Level $36.65 $27.69
Resistance Level $43.26 $32.15
Average True Range (ATR) 1.13 2.54
MACD 0.40 0.29
Stochastic Oscillator 86.93 55.68

Price Performance

Historical Comparison
GSL
SDGR

About GSL Global Ship Lease Inc New

Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Share on Social Networks: